Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav

Phase 4CompletedNCT00519753

Alcon Research522 enrolled

Overview

The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

522

Conditions

Glaucoma

Interventions

Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)DRUG

One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Age related. * Other protocol-defined exclusion criteria may apply.

Locations (1)

Mainz

Mainz, Germany

Outcomes

Primary Outcomes

Change in intraocular pressure at 12 weeks from travoprost prior therapy (baseline)

Time frame: Baseline and 12 weeks

Secondary Outcomes

Change in intraocular pressure at 12 weeks from other prior therapies (baseline)

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.